Adalvo is pleased to announce that the successful Pivotal BE Study for Brivaracetam Film Coated Tablets has been completed, and we are currently preparing for our DCP submission, scheduled for January 2024.
Brivaracetam Film Coated Tablets, has been developed based on the reference brand Briviact. The product is indicated as an adjunctive therapy in the treatment of partial onset seizures.
The brand sold approximately $635 Mn globally in 2022, having a significant growth potential with a Global 3Y CAGR at 17%, according to IQVIA.
With our clearly defined product pathway, we believe we can achieve day-1 launch in all major markets.
Adalvo is working on several interesting CNS projects, as depicted below. This highlights our ability to offer differentiated, value-added products to our partners. We will continue to expand our offerings within this domain, continuously.
Partner up now!
At Adalvo, there are no half measures – we arealways on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
email@example.com – Central & Eastern Europe, Russia & CIS
firstname.lastname@example.org- North Europe, APAC, MENA & Israel
email@example.com – Brazil
firstname.lastname@example.org - LATAM (exc. Brazil) & South Europe
email@example.com – Europe
firstname.lastname@example.org – UK/Ireland, North America & South Africa
email@example.com - LATAM (exc. Brazil)
firstname.lastname@example.org - Head of Global BD&L
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.